Search results for "Propensity Score"

showing 10 items of 129 documents

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

2020

Objective Primary percutaneous coronary intervention (P-PCI) has demonstrated its efficacy in patients with ST segment elevation myocardial infarction (STEMI). However, patients with STEMI >= 75 years receive less P-PCI than younger patients despite their higher in-hospital morbimortality. The objective of this analysis was to determine the effectiveness of P-PCI in patients with STEMI >= 75 years. Methods We included 979 patients with STEMI >= 75 years, from the ATencion HOspitalaria del Sindrome coronario study, a registry of 8142 consecutive patients with acute coronary syndrome admitted at 31 Spanish hospitals in 2014-2016. We calculated a propensity score (PS) for the indication of P-P…

MaleTime FactorsPercutaneoussistema de registrosmedicine.medical_treatmenthumanosComorbidityCoronary Artery Disease030204 cardiovascular system & hematologyLogistic regression0302 clinical medicineRecurrenceRisk Factorsevaluación de riesgosST segmentRegistries1506030212 general & internal medicineMyocardial infarctionAged 80 and overancianocoronary intervention (PCI)resultado del tratamientoCardiogenic shockAge FactorsShockstemiTreatment Outcomesurgical procedures operativeCardiologyFemaleAcute coronary syndromeCardiology and Cardiovascular MedicineStemiAcute coronary syndromemedicine.medical_specialtyShock CardiogenicPulmonary EdemaRisk Assessmentacute coronary syndromeedema pulmonar03 medical and health sciencesfactores de tiempoPercutaneous Coronary Interventionchoquecirugía coronaria percutáneaInternal medicinemedicinefactores de riesgoHumanscardiovascular diseasesAgedCoronary intervention (PCI)business.industryPercutaneous coronary interventionmedicine.diseaseSpainPropensity score matchingST Elevation Myocardial InfarctionbusinessrecurrenciaOpen Heart
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronar…

2019

Background: Nowadays, the majority of patients with myocardial infarction with ST-segment elevation (STEMI) are treated with primary percutaneous coronary interventions (PCI). In recent years, there have been ongoing improvements in PCI techniques, devices and concomitant pharmacotherapy. However, reports on further mortality reduction among PCI-treated STEMI patients remain inconclusive. The aim of this study was to compare changes in management and mortality in PCI-treated STEMI patients between 2005 and 2011 in a real-life setting. Methods: Data on 79,522 PCI-treated patients with STEMI from Polish Registry of Acute Coronary Syndromes (PL-ACS) admitted to Polish hospitals between 2005 an…

MaleTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicinetemporal trendsRisk Factorstreatment strategyST segmentMyocardial infarctionHospital MortalityRegistriesPractice Patterns Physicians'Mortality rateGeneral MedicineMiddle AgedInterventional Cardiologysurgical procedures operativeTreatment OutcomePractice Guidelines as TopicCardiologyFemaleStentsGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyRisk Assessment03 medical and health sciencesPharmacotherapyPercutaneous Coronary InterventionSex FactorsInternal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeHealthcare DisparitiesAgedRetrospective Studiesbusiness.industryPercutaneous coronary interventionCardiovascular AgentsHealth Status Disparitiesmedicine.diseaseST-segment elevation myocardial infarctionConcomitantPropensity score matchingConventional PCI1-year mortalityST Elevation Myocardial InfarctionPolandbusinesssex-differencesin-hospital mortality
researchProduct

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian…

2020

Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatme…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquineEuropean journal of internal medicine
researchProduct

Differential Prognostic Effect of Revascularization According to a Simple Comorbidity Index in High-Risk Non-ST-Segment Elevation Acute Coronary Synd…

2011

Background: Data on the effect of revascularization on outcome in patients with high-risk non–ST-segment elevation acute coronary syndrome (NSTEACS) and significant comorbidities are scarce. Recently, a simple comorbidity index (SCI) including 5 comorbidities (renal failure, dementia, peripheral artery disease, heart failure, and prior myocardial infarction [MI]) has shown to be a useful tool for risk stratification. Nevertheless, therapeutic implications have not been derived. Hypothesis: We sought to evaluate the prognostic effect attributable to revascularization in NSTEACS according the SCI score. Methods: We included 1017 consecutive patients with NSTEACS. The effect of revascularizati…

Malemedicine.medical_specialtyAcute coronary syndromeTime Factorsmedicine.medical_treatmentDecision MakingStatistics as TopicClinical InvestigationsComorbidityKaplan-Meier EstimateRevascularizationRisk AssessmentInterquartile rangeInternal medicineConfidence IntervalsmedicineHealth Status IndicatorsHumansST segmentProspective StudiesMyocardial infarctionAcute Coronary SyndromePropensity ScoreAgedProportional Hazards Modelsbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle AgedPrognosismedicine.diseaseTroponinConfidence intervalSurgerySpainCardiologyFemaleCardiology and Cardiovascular MedicinebusinessClinical Cardiology
researchProduct

Robot-assisted minimally invasive esophagectomy (RAMIE) compared to conventional minimally invasive esophagectomy (MIE) for esophageal cancer: a prop…

2020

SUMMARY Robot-assisted minimally invasive esophagectomy (RAMIE) is increasingly being applied as treatment for esophageal cancer. In this study, the results of 50 RAMIE procedures were compared with 50 conventional minimally invasive esophagectomy (MIE) operations, which had been the standard treatment for esophageal cancer prior to the robotic era. Between April 2016 and March 2018, data of 100 consecutive patients with esophageal carcinoma undergoing modified Ivor Lewis esophagectomy were prospectively collected. All operations were performed by the same surgeon using an identical intrathoracic anastomotic reconstruction technique with the same perioperative management and pain control re…

Malemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentRamielaw.invention03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProcedureslawJournal ArticlemedicineHumansMinimally Invasive Surgical Proceduresesophageal cancerProspective StudiesIvor LewisPropensity ScoreAgedRAMIEMIEbusiness.industryStandard treatmentIncidenceGastroenterologyGeneral MedicineEsophageal cancerMiddle Agedmedicine.diseaseIntensive care unitSurgeryEsophagectomyRegimenTreatment OutcomeEsophagectomy030220 oncology & carcinogenesisPropensity score matchingminimally invasiveLymph Node Excision030211 gastroenterology & hepatologyLymphadenectomyFemalebusinessDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
researchProduct

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

2014

Abstract Aims We evaluated the impact of baseline comorbidities on the effectiveness of duloxetine and anticonvulsants (pregabalin/gabapentin) in patients with painful diabetic neuropathy in clinical care. Methods Outcomes from a 6-month, observational study with 2575 patients initiating/switching DPNP treatment were analyzed post-hoc. Propensity scoring was used to adjust for baseline factors influencing treatment choice in 1523 patients receiving duloxetine or anticonvulsants. Analysis of covariance models with fixed effects for baseline pain, treatment, propensity score, baseline characteristics or comorbidities, and their interaction with treatment were used to estimate LSmean effects o…

Malemedicine.medical_specialtyGabapentinCyclohexanecarboxylic AcidsEndocrinology Diabetes and MetabolismPregabalinPregabalinComorbidityThiophenesDuloxetine Hydrochloridechemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesInternal MedicinemedicineDuloxetineHumansPain ManagementBrief Pain InventoryAminesDepression (differential diagnoses)gamma-Aminobutyric AcidAgedPain MeasurementRetrospective StudiesAnalgesicsbusiness.industryChronic painMiddle Agedmedicine.diseasePrognosisTreatment OutcomechemistryJoint painPropensity score matchingPhysical therapyAnticonvulsantsFemalemedicine.symptomGabapentinbusinessmedicine.drugJournal of diabetes and its complications
researchProduct

Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate

2021

Background: Although an increasing number of prostate cancer (PCa) patients received holmium laser enucleation of the prostate (HoLEP) previously for benign prostatic obstruction (BPO), there is still no evidence regarding the outcomes of radical prostatectomy (RP) in this setting. Objective: To assess functional and oncological results of RP in PCa patients who received HoLEP for BPO previously in a contemporary multi-institutional cohort. Design, setting, and participants: A total of 95 patients who underwent RP between 2011 and 2019 and had a history of HoLEP were identified in two institutions. Functional as well as oncological follow-up was prospectively assessed and retrospectively an…

Malemedicine.medical_specialtyHolmium laser enucleation of the prostate; Localized prostate cancer; Patient-reported outcomes; Radical prostatectomy; Urinary continenceUrologymedicine.medical_treatmentEnucleation030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceLasers Solid-State03 medical and health sciencesBladder outlet obstructionProstate cancerHolmium0302 clinical medicineErectile DysfunctionmedicineHumansRetrospective StudiesProstatectomyLocalized prostate cancerPatient-reported outcomesProstatectomybusiness.industryHazard ratioProstateUrinary continenceOdds ratiomedicine.diseaseRadical prostatectomyHolmium laser enucleation of the prostate030220 oncology & carcinogenesisPropensity score matchingmedicine.symptombusiness
researchProduct